Literature DB >> 25470076

Febrile non-haemolytic transfusion reaction occurrence and potential risk factors among the U.S. elderly transfused in the inpatient setting, as recorded in Medicare databases during 2011-2012.

M Menis1, R A Forshee, S A Anderson, S McKean, R Gondalia, R Warnock, C Johnson, P D Mintz, C M Worrall, J A Kelman, H S Izurieta.   

Abstract

BACKGROUND AND OBJECTIVES: Febrile non-haemolytic transfusion reaction (FNHTR) is an acute transfusion complication resulting in fever, chills and/or rigours. Study's objective was to assess FNHTR occurrence and potential risk factors among inpatient U.S. elderly Medicare beneficiaries, ages 65 and older, during 2011-2012.
MATERIALS AND METHODS: Our retrospective claims-based study utilized large Medicare administrative databases. FNHTR was ascertained via ICD-9-CM diagnosis code, and transfusions were identified by recorded procedure and revenue centre codes. The study ascertained FNHTR rates among the inpatient elderly overall and by age, gender, race, blood components and units transfused. Multivariate logistic regression analyses were used to assess potential risk factors.
RESULTS: Among 4 336 338 inpatient transfusion stays for elderly during 2011-2012, 2517 had FNHTR diagnosis recorded, an overall rate of 58.0 per 100,000 stays. FNHTR rates (per 100,000 stays) varied by age, gender, number of units and blood components transfused. FNHTR rates were substantially higher for RBCs- and platelets-containing transfusions as compared to plasma only. Significantly higher odds of FNHTR were identified with greater number of units transfused (P < 0.01), for females vs. males (OR = 1.15, 95% CI 1.04-1.27), and with 1-year histories of transfusion (OR = 1.25, 95% CI 1.10-1.42), lymphoma (OR = 1.22, 95% CI 1.02-1.46), leukaemia (OR = 1.90, 95% CI 1.56-2.31) and other diseases.
CONCLUSIONS: Our study shows increased FNHTR occurrence among elderly with greater number of units and with RBCs- and platelets-containing transfusions, suggesting need to evaluate effectiveness of prestorage leucoreduction in elderly. The study also suggests importance of prior recipient alloimmunization and underlying health conditions in the development of FNHTR.
© 2014 International Society of Blood Transfusion.

Entities:  

Keywords:  Medicare; administrative databases; elderly; febrile non-haemolytic transfusion reaction; inpatient; potential risk factors

Mesh:

Year:  2014        PMID: 25470076     DOI: 10.1111/vox.12215

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  5 in total

1.  Analyzing real world data of blood transfusion adverse events: Opportunities and challenges.

Authors:  Perrin Jhaveri; Selen Bozkurt; Axel Moyal; Artur Belov; Steven Anderson; Hua Shan; Barbee Whitaker; Tina Hernandez-Boussard
Journal:  Transfusion       Date:  2022-04-19       Impact factor: 3.337

2.  Relationship between allergic sensitisation-associated single-nucleotide polymorphisms and allergic transfusion reactions and febrile non-haemolytic transfusion reactions in paediatric cases.

Authors:  Yuichiro Ide; Ryu Yanagisawa; Jun Kobayashi; Kazutoshi Komori; Kazuyuki Matsuda; Yuji Amano; Yozo Nakazawa; Toshikazu Takeshita; Kazuo Sakashita; Minoru Tozuka
Journal:  Blood Transfus       Date:  2021-02-03       Impact factor: 3.443

3.  Blood transfusion in elderly patients with chronic anemia: a qualitative analysis of the general practitioners' attitudes.

Authors:  Sylvain Le Calvé; Dominique Somme; Joaquim Prud'homm; Aline Corvol
Journal:  BMC Fam Pract       Date:  2017-07-11       Impact factor: 2.497

4.  Proportion of Acute Transfusion Reaction and Associated Factors Among Adult Transfused Patients at Felege Hiwot Compressive Referral Hospital, Bahir Dar, Northwest Ethiopia: A Cross-Sectional Study.

Authors:  Yemataw Gelaw; Berhanu Woldu; Mulugeta Melku
Journal:  J Blood Med       Date:  2020-06-30

5.  Haemovigilance of reactions associated with red blood cell transfusion: comparison across 17 Countries.

Authors:  M A M Rogers; J M Rohde; N Blumberg
Journal:  Vox Sang       Date:  2015-12-21       Impact factor: 2.144

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.